These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36678598)

  • 1. Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma.
    Lynch E; Duffy AG; Kelly RJ
    Pharmaceuticals (Basel); 2023 Jan; 16(1):. PubMed ID: 36678598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
    Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.
    Lyons TG; Ku GY
    Chin Clin Oncol; 2017 Oct; 6(5):53. PubMed ID: 29129093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brave new world-new and emerging treatments for gastric cancer.
    Lynch E; Duffy AG; Kelly RJ
    Chin Clin Oncol; 2023 Oct; 12(5):54. PubMed ID: 37691344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
    Akin Telli T; Bregni G; Camera S; Deleporte A; Hendlisz A; Sclafani F
    Cancer Lett; 2020 Jan; 469():142-150. PubMed ID: 31669518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
    Runkel M; Verst R; Spiegelberg J; Fichtner-Feigl S; Hoeppner J; Glatz T
    BMC Surg; 2021 Jan; 21(1):35. PubMed ID: 33435947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
    Rizzo A; Mollica V; Massari F
    Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
    Lefler DS; Snook AE; Bashir B
    Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
    Jessurun CAC; Vos JAM; Limpens J; Luiten RM
    Front Oncol; 2017; 7():233. PubMed ID: 29034210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Treatment Options in Metastatic Esophageal Carcinoma: Checkpoint Inhibitors in Combination Therapies.
    Casari C; Novysedlak R; Vachtenheim J; Lischke R; Strizova Z
    Pharmacology; 2023; 108(1):37-46. PubMed ID: 36463853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
    Xiong W; Zhao Y; Du H; Guo X
    Front Oncol; 2021; 11():704336. PubMed ID: 34490104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
    Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in immune-based approaches for the treatment of esophagogastric cancer.
    Weadick CS; Duffy AG; Kelly RJ
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):19-31. PubMed ID: 34937483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors.
    Vlachostergios PJ
    Am J Transl Res; 2021; 13(11):12386-12394. PubMed ID: 34956460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.